… encountered in the haemophiliac population fostered research … Importantly, the portion of
haemophiliac patients that … activity [activated prothrombin complex concentrate (APCC, FEIBA)] …

… agents ± known as prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs)
± two decades ago, the management of haemophilia patients with inhibitors to factors VIII or …

… /FVIII complex concentrates in the induction of immune tolerance in patients with haemophilia
… VWF-free FVIII concentrates in haemophilia A patients with inhibitors and predictive factors …

… Activated and non-activated prothrombin complex concentrates are widely used for the
treatment of active bleeding in haemophiliacs with inhibitors (Hedner, 1999). The use of these …

… complex concentrate, aPCC and recombinant activated factor VII, rFVIIa) in patients with
haemophilia and … of arterial or venous thrombotic complications in haemophilic patients [13–15]. …

… for FVIII – activated prothrombin complex concentrate (aPCC) and recombinant … in patients
with high-titre inhibitors, but neither is as effective as FVIII concentrate in haemophilia patients …

… Haemophilia patients with inhibitors are treated for acute bleeding with prothrombin complex
concentrates … prothrombin complex concentrate substitution in patient with hemophilia A. …

… activated prothrombin complex concentrate (aPCC, Feiba®), patients with acquired haemophilia
A (… of 18 consecutive patients with AHA admitted to two Haemophilia centres in Italy. We …

… Patients with haemophilia and inhibitors have bleeding episodes that can be refractory to
home therapy with either activated prothrombin complex concentrate (… severe haemophilia and …

… haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is detectable. Thus,
patients … from prophylaxis with activated prothrombin complex concentrate (aPCC). Potential …